2026-10-07T15:31:45Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33944200 2026-10-02T13:17:33Z category_24490 portal_975 item_type_6 month_year_10_2026

Supplementary material for: Long-Term Efficacy of Abrocitinib For Atopic Dermatitis: 96 Week Results of the JADE EXTEND Study Comparing Patients Receiving Monotherapy With Those Receiving Combination Therapy Including Topical Medication (<i>JAAD</i>) Bob Geng (6291602) Mette Deleuran (3799594) Vimal H. Prajapati (24398799) Akio Tanaka (12544425) Takeshi Fukumoto (8383197) Pinaki Biswas (11375237) Herwig Koppensteiner (252909) Dermatology Atopic dermatitis eczema abrocitinib Cibinqo dermatology Eczema Area and Severity Index EASI Peak Pruritus Numerical Rating Scale PP-NRS Dermatology Life Quality Index DLQI Patient-Oriented Eczema Measure POEM <p dir="ltr">Supplementary material for Long-Term Efficacy of Abrocitinib For Atopic Dermatitis: 96 Week Results of the JADE EXTEND Study Comparing Patients Receiving Monotherapy With Those Receiving Combination Therapy Including Topical Medication<b> </b>manuscript published in the <i>Journal of the American Academy of Dermatology (JAAD).</i></p> 2026-10-02T13:17:33Z Text Journal contribution 10.25454/pfizer.figshare.33944200.v2 https://figshare.com/articles/journal_contribution/Supplementary_material_for_Long-Term_Efficacy_of_Abrocitinib_For_Atopic_Dermatitis_96_Week_Results_of_the_JADE_EXTEND_Study_Comparing_Patients_Receiving_Monotherapy_With_Those_Receiving_Combination_Therapy_Including_Topical_Medication_i_JAA/33944200 CC BY-NC-ND 4.0